Navigation Links
Exhausted B cells fail to fight HIV
Date:7/14/2008

Antibodies stick to HIV particles, preventing them from infecting other cells and triggering their destruction by immune cells. This antibody response starts out strong in HIV-infected individuals but eventually peters out. To find out why, scientists from the National Institute of Allergy and Infectious Diseases examined the cells that make the antibodies, known as B cells.

The group now finds that HIV gradually depletes the numbers of healthy, functional B cells. Individuals who had high levels of HIV in their blood had lots of B cells, but they failed to replicate normally or to produce high-quality antibodies. The fatigued B cells sported a protein called FCRL4, which dampens B cells' ability to respond to infection. How HIV turns on FCRL4 remains to be seen.

HIV is already known to knock out the defensive cells that directly attack and destroy infected cells. This new study reveals yet another way the virus dismantles the immune system.


'/>"/>

Contact: Hema Bashyam
hbashyam@rockefeller.edu
212-327-7053
Journal of Experimental Medicine
Source:Eurekalert

1

GOOD

Page: 1

Related biology news :

1. ESF EURYI award winner aims to stop cancer cells reading their own DNA
2. Newly created cancer stem cells could aid breast cancer research
3. AIDS interferes with stem cells in the brain
4. Clemson scientists shed light on molecules in living cells
5. Social habits of cells may hold key to fighting diseases
6. UF scientists reveal how dietary restriction cleans cells
7. Human derived stem cells can repair rat hearts damaged by heart attack
8. Scientists identify embryonic stem cells by appearance alone
9. Cells united against cancer
10. Pittsburgh scientists identify human source of stem cells with potential to repair muscle
11. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3Munich lab demonstrates diesel truck engine with barely measurable emissions 2Munich lab demonstrates diesel truck engine with barely measurable emissions 3Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 1Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 2Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 3Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 4Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 5Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 6Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 7Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 8Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 9Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 10Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 11Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 12Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 13Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 14Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 15Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 1Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 2Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 3Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 4Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 5Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 6Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 7Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 8Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 9Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 10SC Johnson a Best Company for Working Moms 57985 1SC Johnson a Best Company for Working Moms 57985 2SC Johnson a Best Company for Working Moms 57985 3
Breaking Biology Technology:Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2